S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Get Rid of Your Siri Remote Once and for All This Year
5 Hypergrowth Stocks to Own in 2023 (Ad)pixel
Russia rejects $60-a-barrel cap on its oil, warns of cutoffs
Moldova signs new energy deal that could ease blackout risk
5 Hypergrowth Stocks to Own in 2023 (Ad)pixel
OPEC+ oil producers face uncertainty over Russian sanctions
No OPEC+ oil shakeup as Russian price cap stirs uncertainty
Next-Generation Fighter Jets?!? (Must See) (Ad)pixel
OPEC keeps oil targets amid uncertainty on Russian sanctions
FDA change ushers in cheaper, easier-to-get hearing aids
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Get Rid of Your Siri Remote Once and for All This Year
5 Hypergrowth Stocks to Own in 2023 (Ad)pixel
Russia rejects $60-a-barrel cap on its oil, warns of cutoffs
Moldova signs new energy deal that could ease blackout risk
5 Hypergrowth Stocks to Own in 2023 (Ad)pixel
OPEC+ oil producers face uncertainty over Russian sanctions
No OPEC+ oil shakeup as Russian price cap stirs uncertainty
Next-Generation Fighter Jets?!? (Must See) (Ad)pixel
OPEC keeps oil targets amid uncertainty on Russian sanctions
FDA change ushers in cheaper, easier-to-get hearing aids
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Get Rid of Your Siri Remote Once and for All This Year
5 Hypergrowth Stocks to Own in 2023 (Ad)pixel
Russia rejects $60-a-barrel cap on its oil, warns of cutoffs
Moldova signs new energy deal that could ease blackout risk
5 Hypergrowth Stocks to Own in 2023 (Ad)pixel
OPEC+ oil producers face uncertainty over Russian sanctions
No OPEC+ oil shakeup as Russian price cap stirs uncertainty
Next-Generation Fighter Jets?!? (Must See) (Ad)pixel
OPEC keeps oil targets amid uncertainty on Russian sanctions
FDA change ushers in cheaper, easier-to-get hearing aids
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Get Rid of Your Siri Remote Once and for All This Year
5 Hypergrowth Stocks to Own in 2023 (Ad)pixel
Russia rejects $60-a-barrel cap on its oil, warns of cutoffs
Moldova signs new energy deal that could ease blackout risk
5 Hypergrowth Stocks to Own in 2023 (Ad)pixel
OPEC+ oil producers face uncertainty over Russian sanctions
No OPEC+ oil shakeup as Russian price cap stirs uncertainty
Next-Generation Fighter Jets?!? (Must See) (Ad)pixel
OPEC keeps oil targets amid uncertainty on Russian sanctions
FDA change ushers in cheaper, easier-to-get hearing aids
NASDAQ:DTIL

Precision BioSciences - DTIL Stock Forecast, Price & News

$1.34
+0.01 (+0.75%)
(As of 12/2/2022 12:00 AM ET)
Add
Compare
Today's Range
$1.28
$1.35
50-Day Range
$1.22
$1.58
52-Week Range
$1.11
$9.41
Volume
343,752 shs
Average Volume
492,934 shs
Market Capitalization
$148.69 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.00

Precision BioSciences MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.60 Rating Score
Upside/​Downside
497.0% Upside
$8.00 Price Target
Short Interest
Healthy
1.76% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.99
Upright™ Environmental Score
News Sentiment
0.13mentions of Precision BioSciences in the last 14 days
Based on 4 Articles This Week
Insider Trading
Acquiring Shares
$49,630 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($1.29) to ($0.84) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.44 out of 5 stars

Medical Sector

202nd out of 1,034 stocks

Biological Products, Except Diagnostic Industry

36th out of 171 stocks

DTIL stock logo

About Precision BioSciences (NASDAQ:DTIL) Stock

Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing and ex vivo allogeneic CAR T therapies in the United States. It offers ARCUS, a genome editing platform to cure genetic disorders. The company also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which T cell, a specific type of immune cell is genetically engineered to recognize and kill cancer cells; PBCAR0191, which is in Phase 1/2a clinical trial in adult patients with R/R NHL or R/R B-cell precursor acute lymphoblastic leukemia, or B-ALL; PBCAR19B, an anti-CD19 CAR T candidate built on the stealth cell platform utilizing a single-step gene edit to minimize the risk of chromosome abnormalities; and PBCAR269A, an investigational allogeneic CAR T immunotherapy targeting BCMA for the treatment of R/R multiple myeloma. The company has development and commercial license agreement with Les Laboratoires Servier to develop allogeneic chimeric antigen receptor T cell therapies for antigen targets, hematological cancer targets beyond CD19, and solid tumor targets; Tiziana Life Sciences to evaluate foralumab, a fully human anti-CD3 monoclonal antibody as a lymphodepleting agent for the potential treatment of cancers; and iECURE, Inc. to develop ARCUS-based gene editing therapies. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.

Receive DTIL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Precision BioSciences and its competitors with MarketBeat's FREE daily newsletter.

DTIL Stock News Headlines

Precision BioSciences's Earnings Outlook
Caris' Precision Oncology Alliance Welcomes VCU Massey Cancer Center
See More Headlines
Receive DTIL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Precision BioSciences and its competitors with MarketBeat's FREE daily newsletter.

DTIL Company Calendar

Last Earnings
11/08/2022
Today
12/04/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/21/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:DTIL
Fax
N/A
Employees
198
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$8.00
High Stock Price Forecast
$17.00
Low Stock Price Forecast
$2.00
Forecasted Upside/Downside
+273.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.60
Research Coverage
5 Analysts

Profitability

Net Income
$-30,600,000.00
Net Margins
-505.97%
Pretax Margin
-505.97%

Debt

Sales & Book Value

Annual Sales
$115.53 million
Book Value
$0.76 per share

Miscellaneous

Free Float
101,527,000
Market Cap
$148.69 million
Optionable
Not Optionable
Beta
1.48

Key Executives

  • Mr. Michael Amoroso (Age 44)
    Pres, CEO & Director
    Comp: $876.24k
  • Dr. Derek Jantz Ph.D. (Age 46)
    Co-Founder, Chief Scientific Officer & Strategy
    Comp: $597.38k
  • Mr. John Alexander Kelly (Age 55)
    Chief Financial Officer
    Comp: $691.14k
  • Dr. Jefferson J. Smith Ph.D.
    Co-Founder & Chief Research Officer
  • Mr. Shane Barton (Age 51)
    VP, Corp. Controller & Principal Accounting Officer
  • Mei Burris
    Director of Investor Relations & Fin.
  • Mr. Dario Scimeca (Age 47)
    Gen. Counsel & Sec.
  • Mr. Bruce Stevens
    VP of Quality & Compliance
  • Ms. Heather King
    Director of Marketing Communications & PR
  • Maurissa Messier
    Sr. Director of Corp. Communications













DTIL Stock - Frequently Asked Questions

Should I buy or sell Precision BioSciences stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Precision BioSciences in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" DTIL shares.
View DTIL analyst ratings
or view top-rated stocks.

What is Precision BioSciences' stock price forecast for 2023?

5 brokerages have issued 12-month price objectives for Precision BioSciences' shares. Their DTIL share price forecasts range from $2.00 to $17.00. On average, they expect the company's stock price to reach $8.00 in the next twelve months. This suggests a possible upside of 497.0% from the stock's current price.
View analysts price targets for DTIL
or view top-rated stocks among Wall Street analysts.

How have DTIL shares performed in 2022?

Precision BioSciences' stock was trading at $7.40 at the beginning of 2022. Since then, DTIL shares have decreased by 81.9% and is now trading at $1.34.
View the best growth stocks for 2022 here
.

When is Precision BioSciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 21st 2023.
View our DTIL earnings forecast
.

How were Precision BioSciences' earnings last quarter?

Precision BioSciences, Inc. (NASDAQ:DTIL) issued its quarterly earnings data on Tuesday, November, 8th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.35) by $0.13. The company had revenue of $7.36 million for the quarter, compared to analysts' expectations of $5.37 million. Precision BioSciences had a negative net margin of 505.97% and a negative trailing twelve-month return on equity of 119.45%.

What is Matt Kane's approval rating as Precision BioSciences' CEO?

12 employees have rated Precision BioSciences Chief Executive Officer Matt Kane on Glassdoor.com. Matt Kane has an approval rating of 100% among the company's employees. This puts Matt Kane in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Precision BioSciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Precision BioSciences investors own include Editas Medicine (EDIT), Sorrento Therapeutics (SRNE), Alector (ALEC), Kaleido Biosciences (KLDO), Gossamer Bio (GOSS), Micron Technology (MU), Homology Medicines (FIXX), Heron Therapeutics (HRTX), Inovio Pharmaceuticals (INO) and Invitae (NVTA).

When did Precision BioSciences IPO?

(DTIL) raised $126 million in an initial public offering on Thursday, March 28th 2019. The company issued 7,900,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan, Goldman Sachs, Jefferies and Barclays served as the underwriters for the IPO.

What is Precision BioSciences' stock symbol?

Precision BioSciences trades on the NASDAQ under the ticker symbol "DTIL."

Who are Precision BioSciences' major shareholders?

Precision BioSciences' stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (3.51%), Marshall Wace LLP (2.15%), BlackRock Inc. (2.09%), Renaissance Technologies LLC (1.96%), Moloney Securities Asset Management LLC (0.57%) and UBS Oconnor LLC (0.44%). Insiders that own company stock include Alan List, Christopher Heery, Dario Scimeca, David S Thomson, David S Thomson, Derek Jantz, John Alexander Kelly, Matthew R Kane, Matthew R Kane, Michael Amoroso and Vince Craig Hopkin.
View institutional ownership trends
.

How do I buy shares of Precision BioSciences?

Shares of DTIL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Precision BioSciences' stock price today?

One share of DTIL stock can currently be purchased for approximately $1.34.

How much money does Precision BioSciences make?

Precision BioSciences (NASDAQ:DTIL) has a market capitalization of $148.69 million and generates $115.53 million in revenue each year. The company earns $-30,600,000.00 in net income (profit) each year or ($1.52) on an earnings per share basis.

How many employees does Precision BioSciences have?

The company employs 198 workers across the globe.

How can I contact Precision BioSciences?

Precision BioSciences' mailing address is 302 EAST PETTIGREW STREET SUITE A-100, DURHAM NC, 27701. The official website for the company is www.precisionbiosciences.com. The company can be reached via phone at (919) 314-5512 or via email at jwong@bplifescience.com.

This page (NASDAQ:DTIL) was last updated on 12/4/2022 by MarketBeat.com Staff